Compare VIR & AWF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VIR | AWF |
|---|---|---|
| Founded | 2016 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 825.0M | 924.4M |
| IPO Year | 2019 | N/A |
| Metric | VIR | AWF |
|---|---|---|
| Price | $5.99 | $10.69 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 11 | 0 |
| Target Price | ★ $25.73 | N/A |
| AVG Volume (30 Days) | ★ 2.2M | 190.0K |
| Earning Date | 11-05-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 7.57% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $16,860,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $48.05 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.16 | $9.20 |
| 52 Week High | $14.45 | $10.67 |
| Indicator | VIR | AWF |
|---|---|---|
| Relative Strength Index (RSI) | 46.90 | 41.87 |
| Support Level | $5.73 | $10.61 |
| Resistance Level | $6.11 | $10.75 |
| Average True Range (ATR) | 0.43 | 0.06 |
| MACD | -0.10 | 0.01 |
| Stochastic Oscillator | 19.17 | 31.18 |
Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.
Alliancebernstein Glb High Inc Fund Inc is a United States-based diversified, closed-end management investment company. Its primary investment objective is to seek high current income, and secondarily, capital appreciation. The fund invests in debt securities, including Sovereign Debt Obligations and corporate debt, denominated in non-U.S. currencies as well as in the U.S. Dollar. It may invest without limit in emerging and developed markets and debt securities of U.S. and non-U.S. corporate issuers.